<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Davidson, Nancy E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evidence-Based AET in Women Before and After Menopause</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">The current evidence to guide adjuvant endocrine therapy in women with ER-positive breast cancer, including tamoxifen, aromatase inhibitors, and ovarian function suppression is reviewed. The studies include ATLAS, aTTom, SOFT, ECOG E3193, TEXT, ABCSG 12, and the Early Breast Cancer Trialists’ Collaborative Group meta-analysis.</style></abstract><number><style face="normal" font="default" size="100%">56</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>